Pulse Versus Daily Oral Cyclophosphamide in ANCA-Associated Vasculitis

Abstract

Letters5 January 2010Pulse Versus Daily Oral Cyclophosphamide in ANCA-Associated VasculitisStuart M. Levine, MDStuart M. Levine, MDFrom Johns Hopkins University, Baltimore, MD 21218.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-1-201001050-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The study by de Groot and colleagues (1) shows that the higher cumulative dosing of traditional (2 mg/kg) daily oral cyclophosphamide regimens offers no advantage over lower-dose regimens delivered by intravenous pulse for the induction of remission in patients with ANCA-associated vasculitis. However, the authors did not evaluate whether lower-dose (1.0 to 1.25 mg/kg) daily oral regimens, with their lower risks for bone marrow and bladder toxicities, would be similarly efficacious in achieving remission. Before intravenous pulse cyclophosphamide for induction of remission in this patient population is broadly recommended, comparison studies with less toxic oral regimens are ...Reference1. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670-80. [PMID: 19451574] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Johns Hopkins University, Baltimore, MD 21218.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated Vasculitis Kirsten de Groot , Lorraine Harper , David R.W. Jayne , Luis Felipe Flores Suarez , Gina Gregorini , Wolfgang L. Gross , Rashid Luqmani , Charles D. Pusey , Niels Rasmussen , Renato A. Sinico , Vladimir Tesar , Philippe Vanhille , Kerstin Westman , Caroline O.S. Savage , and Pulse Versus Daily Oral Cyclophosphamide in ANCA-Associated Vasculitis Lorraine Harper , Kirsten de Groot , and Caroline O. Savage Pulse Versus Daily Oral Cyclophosphamide in ANCA-Associated Vasculitis Prasanta Padhan Pulse Versus Daily Oral Cyclophosphamide in ANCA-Associated Vasculitis Lee A. Hebert and Brad H. Rovin Metrics Cited ByPauci-Immune Necrotizing Glomerulonephritis 5 January 2010Volume 152, Issue 1Page: 65KeywordsBladderBone marrowConflicts of interestCyclophosphamideHeart rateToxicityVasculitis ePublished: 5 January 2010 Issue Published: 5 January 2010 CopyrightCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...